Elevated serum tyrosine concentration is associated with a poor prognosis among patients with liver cirrhosis

2021 ◽  
Author(s):  
Sho Sato ◽  
Nozomi Amano ◽  
Shunsuke Sato ◽  
Yuji Kita ◽  
Yuji Ikeda ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Poor Prognosis ◽  
Elevated Serum ◽  
Tyrosine Concentration

scholarly journals B7-H6 Is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 33-33
Author(s):  
Lei Yuan ◽  
Lu Sun ◽  
Yu Zhao ◽  
Hongmei Jing ◽  
Xiaoyan Ke
Keyword(s):  
Cell Proliferation ◽  
Therapeutic Target ◽  
Poor Prognosis ◽  
Elevated Serum ◽  
Lymphoblastic Lymphoma ◽  
Jurkat Cells ◽  
Migration And Invasion ◽  
Serum Lactate Dehydrogenase ◽  
Nuclear Localization Sequence ◽  
The Impact

Background:B7-H6 is a novel co-stimulatory protein that is exclusively expressed on a variety of cancer cells and associated with poor prognosis. T cell lymphoblastic lymphoma (T-LBL) is a highly aggressive hematological malignancy whose treatment requires reliable prognostic biomarkers and therapeutic targets. The rare nature and delayed progression of T-LBL has limited its clinical management. Methods:B7-H6 expression was analyzed by immunohistochemistry (IHC) in 65 T-LBL samples, and its association with clinicopathological characteristics and prognosis was analyzed. Jurkat cell with B7-H6 depletion was constructed to investigate the impact of B7-H6 on cell proliferation, migration, and invasion ability. RNA sequencing was used to explore aberrantly expressing genes. Results:In this study, we used immunohistochemistry to show the expression of B7-H6 in 61.5% (40/65) of the cohort, including 38.5% (25/65) patients with membrane/cytoplasmic expression of B7-H6. Although B7-H6 expression varied across samples and did not correlate with patient survival, it was significantly associated with B symptoms, higher ECOG score (3-4), elevated serum lactate dehydrogenase, and reduced complete remission at interim evaluation. B7-H6 underwent translocation into the nucleus of T-LBL cells and had a specific nuclear localization sequence in the C-terminus. Depleting Jurkat cells of B7-H6 impaired cell proliferation, migration, and invasion. RNAseq showed the differential expression of RAG-1 that could be involved in the tumorigenesis of T-LBL. Conclusions:B7-H6 may serve as a novel prognostic biomarker and therapeutic target of T-LBL. Disclosures Ke: Peking University Third Hospital:Current Employment.

Septic epiphysitis and sequestrum formation in the glenoid of the scapula in a five-month-old foal diagnosed by computed tomography

2019 ◽  
Vol 7 (3) ◽  
pp. e000837
Author(s):  
Peter E Clements ◽  
Becky Jones ◽  
Richard Coomer
Keyword(s):  
Poor Prognosis ◽  
Serum Amyloid A ◽  
Proximal Humerus ◽  
Treatment Options ◽  
Elevated Serum ◽  
Acute Onset ◽  
Subchondral Bone Plate ◽  
Large Defect ◽  
Amyloid A ◽  
Bony Fragment

A five-month-old Connemara foal presented for acute-onset, severe left forelimb lameness with fever, neutrophilia and an elevated serum amyloid A concentration. Radiographs were suspicious of septic physitis of the proximal humerus. CT identified a large defect involving the central portion of the subchondral bone plate of the glenoid and a sequestered bony fragment within the defect, which were not seen radiographically. CT findings were consistent with septic epiphysitis and sequestrum formation, which had significant implications on available treatment options. The foal was given a poor prognosis for returning to soundness so was subject to humane euthanasia.

scholarly journals Serum Endocan as a Survival Predictor for Patients with Liver Cirrhosis

2015 ◽  
Vol 29 (8) ◽  
pp. 427-430 ◽  
Author(s):  
Nobuyuki Toshikuni ◽  
Kazuaki Ozaki ◽  
Joseph George ◽  
Mikihiro Tsutsumi
Keyword(s):  
Liver Cirrhosis ◽  
Proportional Hazards Model ◽  
Survival Rates ◽  
Elevated Serum ◽  
Cox Proportional Hazards Model ◽  
Rank Test ◽  
Hepatic Decompensation ◽  
Cumulative Survival ◽  
Kaplan Meier ◽  
Survival Predictor

BACKGROUND: The relationship between endocan expression and outcome in patients with chronic liver disease is not fully understood.OBJECTIVE: To examine whether serum endocan level is predictive of outcome in patients with liver cirrhosis.METHODS: A total of 68 patients with liver cirrhosis were enrolled. Outcome predictors were analyzed using the Cox proportional hazards model. The overall survival rates were calculated using the Kaplan-Meier method, and differences were evaluated using the log-rank test.RESULTS: During the median follow-up period (7.1 years), nine patients had hepatocellular carcinoma (HCC) and 10 patients died. Of the deceased patients, nine died due to hepatic decompensation or associated conditions. No significant factors were found to be predictive of the occurrence of HCC. In contrast, an elevated serum endocan level (≥2.0 ng/mL; HR 2.34 [95% CI 1.05 to 7.03]; P=0.037) and high Child-Pugh grade B/C (HR 2.65 [95% CI 1.30 to 6.89; P=0.006) were predictive of poor survival. Kaplan-Meier analysis revealed that the respective cumulative survival rates at five and 10 years were 97.1% and 87.4% in patients with serum endocan levels <2.0 ng/mL and 85.8% and 64.4% in patients with levels ≥2.0 ng/mL (P=0.009), respectively. Moreover, the cumulative survival rates were significantly different among the patient groups divided according to serum endocan level and Child-Pugh grade (P=0.002).CONCLUSION: These findings suggest that serum endocan level may be a survival predictor for patients with liver cirrhosis.

scholarly journals Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis

2018 ◽  
Vol 24 (4) ◽  
pp. 409-416 ◽  
Author(s):  
Soon Kyu Lee ◽  
Myeong Jun Song ◽  
Seok Hwan Kim ◽  
Hyo Jun Ahn
Keyword(s):  
Liver Cirrhosis ◽  
Diastolic Dysfunction ◽  
Poor Prognosis ◽  
Decompensated Liver Cirrhosis

scholarly journals Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Thit Mynster Kronborg ◽  
Henriette Ytting ◽  
Lise Hobolth ◽  
Søren Møller ◽  
Nina Kimer
Keyword(s):  
Liver Cirrhosis ◽  
Chronic Inflammation ◽  
Poor Prognosis ◽  
Current Treatment ◽  
Gut Microflora ◽  
Rodent Models ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Human Trials ◽  
Anti Inflammatory

Liver cirrhosis is a disease characterised by multiple complications and a poor prognosis. The prevalence is increasing worldwide. Chronic inflammation is ongoing in liver cirrhosis. No cure for the inflammation is available, and the current treatment of liver cirrhosis is only symptomatic. However, several different medical agents have been suggested as potential healing drugs. The majority are tested in rodents, but few human trials are effectuated. This review focuses on medical agents described in the literature with supposed alleviating and curing effects on liver cirrhosis. Twelve anti-inflammatory, five antioxidative, and three drugs with effects on gut microflora and the LPS pathway were found. Two drugs not categorised by the three former categories were found in addition. In total, 42 rodent studies and seven human trials were found. Promising effects of celecoxib, aspirin, curcumin, kahweol, pentoxifylline, diosmin, statins, emricasan, and silymarin were found in cirrhotic rodent models. Few indices of effects of etanercept, glycyrrhizin arginine salt, and mitoquinone were found. Faecal microbiota transplantation is in increasing searchlight with a supposed potential to alleviate cirrhosis. However, human trials are in demand to verify the findings in this review.

scholarly journals Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242582
Author(s):  
Akira Sakamaki ◽  
Kunihiko Yokoyama ◽  
Kyutaro Koyama ◽  
Shinichi Morita ◽  
Hiroyuki Abe ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Liver Cirrhosis ◽  
Subcutaneous Adipose Tissue ◽  
Poor Prognosis ◽  
Cox Regression ◽  
Total Bilirubin Level ◽  
Alcoholic Liver Cirrhosis ◽  
Poor Prognostic Factor ◽  
Cox Regression Analysis ◽  
Subcutaneous Adipose

In alcoholic liver cirrhosis (LC) patients, obesity has become a problem that progresses into liver dysfunction. Herein, we investigated the relationship between the prognosis of steatohepatitis and body weight, along with fat accumulation in patients with alcoholic LC. We conducted a single-center retrospective study, enrolled 104 alcoholic LC patients without hepatocellular carcinoma (HCC) based on histological and clinical evidence, and investigated factors related to poor prognosis using multivariate Cox regression and cluster analyses. Cox regression analysis revealed three independent relevant factors: subcutaneous adipose tissue (SAT) index (median 34.8 cm2/m2, P = 0.009, hazard ratio [HR] 1.017, 95% confidence interval [CI] 1.004–1.030), total bilirubin level (median 1.7 mg/dL, P = 0.003, HR 1.129, 95% CI 1.042–1.223), and prothrombin time value (median 64%, P = 0.007, HR 0.967, 95% CI 0.943–0.991). In the cluster analysis, we categorized the patients into three groups: no adipose tissue accumulation (NAT group), SAT prior accumulation (SAT group), and visceral adipose tissue prior accumulation (VAT group). The results of the three groups revealed that the SAT group displayed a significantly poor prognosis of the Kaplan–Meier curve (67.1 vs 21.2 vs 65.3, P<0.001) of a 5-year survival rate. Propensity score matching analysis of the SAT and VAT groups was performed to adjust the patient’s background, but no significant differences were found between them; however, the prognosis was poorer (21.2 vs 66.3, P<0.001), and hemostatic factors were still at a lower level in the SAT group. These findings suggest that SAT accumulation type of obesity is a poor prognostic factor in alcoholic LC patients without HCC, and the hemorrhagic tendency might worsen the poor prognosis in such cases.

scholarly journals Elevated PCT at ICU discharge predicts poor prognosis in patients with severe traumatic brain injury: a retrospective cohort study

2020 ◽  
Vol 48 (5) ◽  
pp. 030006052092245
Author(s):  
Yu-rong Wang ◽  
Qing-bin Zheng ◽  
Guang-fa Wei ◽  
Li-jun Meng ◽  
Qing-ling Feng ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Cohort Study ◽  
Brain Injury ◽  
Severe Traumatic Brain Injury ◽  
Poor Prognosis ◽  
Clinical Decision Making ◽  
Elevated Serum ◽  
Adverse Outcomes ◽  
Apache Ii Score ◽  
Icu Discharge

Purpose Disease severity and inflammatory response status are closely related to a poor prognosis and must be assessed in patients with severe traumatic brain injury (STBI) before intensive care unit (ICU) discharge. Whether elevated serum procalcitonin (PCT) levels can predict a poor prognosis in STBI patients before ICU discharge is unclear. Methods This retrospective observational cohort study enrolled 199 STBI patients who were in the ICU for at least 48 hours and survived after discharge. Based on serum PCT levels at discharge, patients were divided into the high-PCT group (PCT ≥ 0.25 ng/mL) and the low-PCT group (PCT < 0.25 ng/mL). We assessed the relationship between serum PCT levels and a poor prognosis. Results The high-PCT group had a higher rate of adverse outcomes compared with the low-PCT group. Multivariate logistic regression analysis showed that the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score, white blood cell (WBC) count, C-reactive protein (CRP) level, and PCT level at discharge were significantly associated with adverse outcomes. Conclusions Elevated PCT levels at ICU discharge were associated with a poor prognosis in STBI patients. The serum PCT level as a single indicator has limited value for clinical decision-making.

scholarly journals Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1805
Author(s):  
Jun Sik Yoon ◽  
Dong Ho Lee ◽  
Eun Ju Cho ◽  
Mi Kyoung Song ◽  
Young Hun Choi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Cumulative Incidence ◽  
Rare Complication ◽  
Fontan Procedure ◽  
Fontan Operation ◽  
Late Complication ◽  
Elevated Serum ◽  
Arterial Phase ◽  
Portal Venous Phase

Liver cirrhosis and hepatocellular carcinoma (HCC) are serious late complications that can occur after the Fontan procedure. This study aimed to investigate the cumulative incidence of cirrhosis and HCC and to identify specific features distinguishing HCC from benign arterial-phase hyperenhancing (APHE) nodules that developed after the Fontan operation. We retrospectively enrolled 313 post-Fontan patients who had been followed for more than 5 years and had undergone ultrasound or computed tomography (CT) of the liver between January 2000 and August 2018. Cirrhosis was diagnosed radiologically. The estimated cumulative incidence rates of cirrhosis at 5, 10, 20, and 30 years after the Fontan operation were 1.3%, 9.2%, 56.6%, and 97.9%, respectively. Multiphasic CT revealed that 18 patients had APHE nodules that were ≥1 cm in size and showed washout in the portal venous phase (PVP)/delayed phase, which met current noninvasive HCC diagnosis criteria. Among them, only seven patients (38.9%, 7/18) were diagnosed with HCC. After cirrhosis developed, the annual incidence of HCC was 1.04%. The appearance of washout in the PVP (p = 0.006), long time elapsed since the initial Fontan operation (p = 0.04), large nodule size (p = 0.03), and elevated serum α-fetoprotein (AFP) level (p < 0.001) were significantly associated with HCC. In conclusion, cirrhosis is a frequent late complication after Fontan operation, especially after 10 years, and HCC is not a rare complication after cirrhosis development. Diagnosis of HCC should not be based solely on the current imaging criteria, and washout on PVP and clinical features might be helpful to differentiate HCC nodules from benign APHE nodules.

Sign in / Sign up

Export Citation Format

Share Document